Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
TP-0903 is active in models of drug-resistant acute myeloid leukemia
Jae Yoon Jeon, … , Bhavana Bhatnagar, Sharyn D. Baker
Jae Yoon Jeon, … , Bhavana Bhatnagar, Sharyn D. Baker
Published December 3, 2020
Citation Information: JCI Insight. 2020;5(23):e140169. https://doi.org/10.1172/jci.insight.140169.
View: Text | PDF
Research Article Hematology Oncology

TP-0903 is active in models of drug-resistant acute myeloid leukemia

  • Text
  • PDF
Abstract

Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance. Here, we report that TP-0903 has potent activity against protein kinases related to STAT, AKT, and ERK signaling, as well as cell cycle regulators in biochemical and cellular assays. In vitro and in vivo, TP-0903 was active in multiple models of drug-resistant FLT3 mutant AML, including those involving the F691L gatekeeper mutation and bone marrow microenvironment–mediated factors. Furthermore, TP-0903 demonstrated preclinical activity in AML models with FLT3-ITD and common co-occurring mutations in IDH2 and NRAS genes. We also showed that TP-0903 had ex vivo activity in primary AML cells with recurrent mutations including MLL-PTD, ASXL1, SRSF2, and WT1, which are associated with poor prognosis or promote clinical resistance to AML-directed therapies. Our preclinical studies demonstrate that TP-0903 is a multikinase inhibitor with potent activity against multiple drug-resistant models of AML that will have an immediate clinical impact in a heterogeneous disease like AML.

Authors

Jae Yoon Jeon, Daelynn R. Buelow, Dominique A. Garrison, Mingshan Niu, Eric D. Eisenmann, Kevin M. Huang, Megan E. Zavorka Thomas, Robert H. Weber, Clifford J. Whatcott, Steve L. Warner, Shelley J. Orwick, Bridget Carmichael, Emily Stahl, Lindsey T. Brinton, Rosa Lapalombella, James S. Blachly, Erin Hertlein, John C. Byrd, Bhavana Bhatnagar, Sharyn D. Baker

×

Figure 2

TP-0903 is active in FLT3-mutated AML.

Options: View larger image (or click on image) Download as PowerPoint
TP-0903 is active in FLT3-mutated AML.
(A) Activity of TP-0903 in FLT3-m...
(A) Activity of TP-0903 in FLT3-mutated AML cell lines (MTT assay, 72 hours, n = 18). The IC50 and mutations present in each cell line are listed. (B and C) Quantification of cell cycle phase (B) and mean (± SEM) annexin-V–positive cells (C) at the designated treatment times with TP-0903 (20 nM; n = 3). (D) Cell differentiation measured by expression of CD11b after treatment with TP-0903 (20 nM) for 72 hours. (E and F) Bioluminescence signal (mean ± SEM) (left panels) and survival (Kaplan-Meier analysis) (right panels) following treatment with TP-0903 (60 mg/kg), gilteritinib (30 mg/kg), or vehicle in MOLM13-Luc+ (n = 5/cohort) and MOLM13-RES-Luc+ (n = 10/cohort) NSG mouse xenograft models. Black bars depict treatment days. P values were determined using either unpaired 2-tailed Student’s t test (C and E), 1-way ANOVA (P < 0.0001; F) with Tukey multiple comparison test or log rank test (F; survival curve). Specific P values are indicated within the figure.
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts